Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Down syndrome, caused by trisomy of chromosome 21, is the single most common risk factor for early-onset Alzheimer's disease. Worldwide approximately 6 million people have Down syndrome, and all these individuals will develop the hallmark amyloid plaques and neurofibrillary tangles of Alzheimer's disease by the age of 40 and the vast majority will go on to develop dementia. Triplication of APP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer's disease in the absence of Down syndrome. However, whether triplication of other chromosome 21 genes influences disease pathogenesis in the context of Down syndrome is unclear. Here we show, in a mouse model, that triplication of chromosome 21 genes other than APP increases amyloid-β aggregation, deposition of amyloid-β plaques and worsens associated cognitive deficits. This indicates that triplication of chromosome 21 genes other than APP is likely to have an important role to play in Alzheimer's disease pathogenesis in individuals who have Down syndrome. We go on to show that the effect of trisomy of chromosome 21 on amyloid-β aggregation correlates with an unexpected shift in soluble amyloid-β 40/42 ratio. This alteration in amyloid-β isoform ratio occurs independently of a change in the carboxypeptidase activity of the γ-secretase complex, which cleaves the peptide from APP, or the rate of extracellular clearance of amyloid-β. These new mechanistic insights into the role of triplication of genes on chromosome 21, other than APP, in the development of Alzheimer's disease in individuals who have Down syndrome may have implications for the treatment of this common cause of neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Trisomy of chromosome 21 promotes the intracellular and extracellular deposition of amyloid-β. (A and B) Intracellular amyloid-β deposition (82E1) was increased by trisomy in hippocampal CA3 pyramidal neurons in 4.5–6.5-month-old mice [ANOVA trisomy-tgAPP interaction F(1,31) = 5.125, P = 0.031] [Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.012; wild-type (WT) (black circles) n = 10, trisomic (blue squares) n = 10, tgAPP (red triangles) n = 10, trisomic;tgAPP (purple inverted triangles) n = 10]. (C) A trend for increased hippocampal Tris-soluble multimeric amyloid-β (82E1-82E1 ELISA) normalized to the sum of amyloid-β38, amyloid-β40 and amyloid-β42 in trisomic;tgAPP was observed [trisomy F(1,24) = 3.928, P = 0.059; tgAPP n = 8, trisomic;tgAPP n = 11)]. (D–I) Amyloid-β deposition (6F/3D) in the hippocampus was quantified at (D–F) 6 and (G–I) 16 months of age. Trisomy increases (E and H) the number of plaques [tgAPP–trisomy interaction F(1,77) = 6.744, P = 0.011, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.008, 16 months P = 0.003] and (F and I) the area covered by amyloid-β [tgAPP–trisomy interaction F(1,85) = 4.005, P = 0.049, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.097, 16 months P = 0.037] (6 months wild-type n = 8, trisomic = 8, tgAPP n = 15, trisomic;tgAPP n = 13; 16 months wild-type n = 16, trisomic = 9, tgAPP n = 13, trisomic;tgAPP n = 11). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were studied and sex was included as a factor in the ANOVA. Scale bar in A = 50 µm; D and G = 500 µm. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/c172967425154239b3614fe878be331a/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-1.jpg)
![Figure 2 Trisomy of chromosome 21 promotes the aggregation of amyloid-β. (A–F) Cortical proteins from 16-month-old mice were fractionated and 5 M guanidine hydrochloride soluble amyloid-β quantified by (A–E) Meso Scale Discovery Assay or (F) mass spectrometry. (A and B) No effect of trisomy on amyloid-β38 [tgAPP-trisomy interaction F(1,28) = 0.385, P = 0.540] or amyloid-β40 [tgAPP-trisomy interaction F(1,28) = 0.962, P = 0.355] was observed, (C) but significantly more amyloid-β42 was detected in trisomic;tgAPP mice [tgAPP-trisomy interaction F(1,28) = 5.573, P = 0.025] (Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.005, wild-type n = 6, trisomic = 6, tgAPP n = 13, trisomic;tgAPP n = 11). (D and E) No change in the amyloid-β38/42 ratio [trisomy F(1,19) = 0.072, P = 0.792] or amyloid-β40/42 ratio [trisomy F(1,19) = 0.047, P = 0.831] was observed. (F) The relative abundance of different forms of amyloid-β peptides was not altered by trisomy of chromosome 21 (tgAPP n = 12, trisomic;tgAPP n = 10). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a factor in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/7de3168d568a462da08e5c9eb594be35/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-2.jpg)
![Figure 3 Trisomy of chromosome 21 exacerbates APP/amyloid-β-associated cognitive deficits. (A and B) Exposure to a novel open field was used as a test of activity and habituation (6 months, wild-type n = 28, trisomic n = 28, TgAPP n = 20, trisomic;tgAPP n = 18). (A) Overall activity: ANOVA of distance travelled revealed a main effect of tgAPP [F(1,78) = 26.250, P < 0.001], trisomy [F(1,78) = 9.246, P = 0.003], and a tgAPP-trisomy interaction [F(1,78) = 7.818, P = 0.007] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P = 0.008). (B) The total distance moved declined with exposure time (1-min time bins) ANOVA: main effect of time bin [F(29,2262) = 12.399 P < 0.001]; an interaction of time bin × trisomy [ANOVA F(29,2262) = 1.789 P = 0.006], time bin × tgAPP [F(29,2262) = 1.560 P = 0.029] and time bin × trisomy;tgAPP [F(29,2262) = 1.983, P < 0.001] was observed by ANOVA. (C and D) A Y-maze spatial novelty preference task (1-min delay) was used as a test of activity and memory. (Cohort B 2–3 months and Cohort A 6–7 months, the effect of genotype was similar in both cohorts so data were combined for analysis, wild-type n = 45, trisomic n = 43, TgAPP n = 36, trisomic;tgAPP n = 26). (C) ANOVA of the number of arm entries (test phase), revealed a main effect of trisomy [F(1,89) = 50.360, P < 0.001], tgAPP [F(1,89) = 47.001, P < 0.001], and a tgAPP–trisomy interaction [F(1,89) = 31.720, P < 0.001] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P < 0.001). (D) A preference ratio of 0.5 indicates chance performance (black dotted line). ANOVA of novelty preference revealed a main effect of trisomy [F(1,89) = 10.144 P = 0.002], tgAPP [F(1,89) = 9.312 P = 0.003] and a tgAPP–trisomy interaction [F(1,89) = 5.736, P = 0.019] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001 and trisomic P = 0.010). Performance of tgAPP–trisomic mice was above chance (one-sample t-test t = 3.287 P < 0.001). (E) A discrete-trial, longitudinal spontaneous alternation task in a T-maze was used as a test of memory, 50% alternation represents chance performance (black dotted line) (2–3 months wild-type n = 29, trisomic n = 30, TgAPP n = 21, trisomic;tgAPP n = 17, 6–7 months wild-type n = 28, trisomic n = 29, TgAPP n = 20, trisomic;tgAPP n = 17, 15–16 months wld-type n = 27, trisomic n = 26, TgAPP n = 27, trisomic;tgAPP n = 11). ANOVA of alternation showed a main effect of trisomy [F(1,67) = 7.084 P = 0.010], and an interaction of tgAPP–trisomy [F(1,67) = 4.706, P = 0.034] (Bonferroni pairwise comparison trisomic;tgAPP with wild-type P = 0.032). Performance of tgAPP-trisomic mice was above chance (one-sample t-test, 2–3 months t = 5.884 P < 0.001, 6–7 months t = 5.378 P < 0.001, 15–16 months t = 6.495 P < 0.001). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/0728074d79e94df39d2ed6dbe5f83fa1/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-3.jpg)
![Figure 4 Trisomy of chromosome 21 genes other than APP does not increase APP abundance nor alter β-CTF/α-CTF ratio. (A, B and D) Full-length APP (FL-APP), APP β-CTF and APP α-CTF were measured in cortex (wild-type n = 17, trisomic n = 16, tgAPP n = 24, trisomic;tgAPP n = 19) and hippocampus (wild-type n = 11, trisomic n = 12, tgAPP n = 24, trisomic;tgAPP n = 17) at 3 months of age. (A) Full-length APP was higher in tgAPP and trisomic;tgAPP compared with wild-type or trisomic mice [cortex F(1,68) = 87.667, P < 0.001, hippocampus F(1,56) = 94.301, P < 0.001]. Trisomy did not alter full-length APP [trisomy–tgAPP interaction, cortex F(1,68) = 0.483, P = 0.489, hippocampus F(1,56) = 2.457, P = 0.123]. (B and C) In male mice, APP-CTF/full-length APP ratio was altered (cortex tgAPP n = 17, trisomic;tgAPP n = 11, hippocampus tgAPP n = 14, trisomic;tgAPP n = 8) β-CTF/full-length APP (t-test cortex P = 0.005, hippocampus P = 0.0217) and α-CTF/full-length APP (t-test cortex P = 0.005 hippocampus P < 0.001). (D) Trisomy did not alter the β-CTF/α-CTF ratio in the cortex [trisomy F(1,37) = 0.065, P = 0.799] or hippocampus [trisomy F(1,37) = 1.082, P = 0.305]. (B) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. WT = wild-type.](https://figures.cochat.ai/paper-figures/3778828581a64b7596da739983aabf31/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-4.jpg)
![Figure 5 Trisomy of chromosome 21 genes other than APP does not alter α-/β-secretase activity. Trisomy did not alter (A) soluble β-APP abundance [trisomy F(1,24) = 0.790, P = 0.383, trisomy-tgAPP interaction F(1,24) = 0.773, P = 0.388, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14], (B and C) cortical BACE1 abundance [trisomy F(1,24) = 0.002, P = 0.963; trisomy–tgAPP interaction F(1,24) = 0.071, P = 0.792, wild-type n = 6, trisomic n = 6, TgAPP n = 9, trisomic;tgAPP n = 7], (D) BACE1 β-secretase activity [trisomy F(1,13) = 0.006, P = 0.941; trisomy–tgAPP interaction F(1,13) = 0.001 P = 0.971, wild-type n = 6, trisomic n = 6, TgAPP n = 4, trisomic;tgAPP n = 5], or (E) soluble α-APP abundance [trisomy F(1,27) = 0.041, P = 0.841; trisomy–tgAPP interaction F(1,27) = 0.002, P = 0.969, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14]. (C) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM. Both sexes were analysed and sex was included as a factor in the ANOVA. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/b3aef28883bf4eaa91210dbb2249b115/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-5.jpg)

![Figure 7 Trisomy of chromosome 21 modulates amyloid-β ratios in vivo independently of modulation of γ-secretase activity. (A–C) Tris-soluble amyloid-β38, amyloid-β40 and amyloid-β42 were measured by Meso Scale Discovery 6E10 Aβ Triplex assay in 2-month-old hippocampus (wild-type n = 24, trisomic n = 22, TgAPP n = 25 and trisomic;tgAPP n = 27). (A) Trisomy decreased amyloid-β38 [trisomy F(1,4) = 15.403, P = 0.017] and amyloid-β40 [trisomy F(1,11) = 6.359, P = 0.028], but amyloid-β42 was not changed [trisomy F(1,11) = 2.978, P = 0.112], (B) resulting in an alteration in the amyloid-β38/42 ratio [trisomy F(1,4) = 14.553, P = 0.019] and (C) the amyloid-β40/42 ratio [trisomy F(1,10) = 95.694, P < 0.001]. (D) Hippocampal amyloid-β40/42 ratio negatively correlates with the relative abundance of aggregated amyloid-β (multimeric 82E1-82E1 amyloid-β ELISA) (linear correlation, R2 = 0.5485, P = 0.0003, tgAPP n = 8, trisomic;tgAPP n = 11). Trisomy did not alter the carboxypeptidase activity of the γ-secretase complex, as measured by (E and G) amyloid-β38/42 and (F and H) amyloid-β40/42 ratios produced in vitro by the complex isolated from cortex from (E and F) the Tc1 trisomic mouse [trisomy amyloid-β38/42 F(1,11) = 4.88, P = 0.499; amyloid-β42/40 F(1,11) = 0.799, P = 0.395, wild-type = 9, trisomic = 9] and (G and H) people with Down syndrome and Alzheimer’s disease (AD-DS) (n = 6) compared with age- and sex-matched individuals who did not have Down syndrome or dementia (control n = 6) [trisomy amyloid-β38/42 F(1,5) = 0.102, P = 0.763; amyloid-β42/40 F(1,5) = 0.187, P = 0.684]. (A–F) Data are represented as mean ± SEM, (G and H) individual cases plotted, horizontal line indicates mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and females were studied and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/ab4297bc73604e059748d7a5a4125e9e/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, it has been shown in preclinical models of DS-AD that triplication of HSA21 genes modulates Aβ aggregation and APP transgene-associated mortality independently of an extra copy of APP.17,18”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have indicated that an additional copy of HSA21 genes can alter APP biology, including Aβ deposition in other APP transgenic models.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence in preclinical models demonstrates that genes other than APP being in three copies modify aspects of DSAD, such as cognition and amyloid-β load [1, 50, 70]”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [70]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD brain, markers of ER stress are elevated and correlate with progression of this disorder53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In response to abnormal elevated levels of misfolded proteins and/or free Ca2+ in the ER lumen, the unfolded protein response (UPR) is engaged53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“J20-tgAPP mice overexpress a human APP transgene with Alzheimer’s disease mutations and accumulates amyl- oid-b within the brain from (cid:5) 4–5 months of age (Mucke et al. , 2000).”
Preparation of PCR-Quality Mouse Genomic DNA with Hot Sodium Hydroxide and Tris (HotSHOT)
Truett, G. E., Heeger, P., Mynatt, R. L., Truett, A. A., Walker, J. A., & Warman, M. L. (2000) · BioTechniques · doi:10.2144/00291bm09 · Cited by 1,738 · cited 1×
“DNA was extracted from tail tip or ear biopsy by the Hot Shot method (Truett et al. , 2000).”
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · cited 1×
“(Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) making it likely that three copies of APP are important in the development of Down syndrome–Alzheimer’s disease.”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“In vivo microdialysis In vivo microdialysis was used to assess brain interstitial fluid (interstitial fluid) amyloid-b40 half-life in awake mice as previously described (Castellano et al., 2011).”
MethodInfluentialSelf-citationTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Ts65Dn or Dp(10)1Yey;Dp(16)1Yey;Dp(17)1Yey triple trisomic mice] do not form amyloid-b plaques even in elderly mice (26 months) (Reeves et al., 1995; Yu et al., 2010).”
T-maze alternation in the rodent
Deacon, R. M. J., & Rawlins, J. N. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.2 · Cited by 897 · cited 1×
“A T-shaped maze made of wood painted dark grey with 30 (cid:2) 10 (cid:2) 29 cm arms, with a central partition extending 7 cm into the start arm from the back of the maze, was used to assess spontaneous alternation as previously described (Deacon and Rawlins, 2006).”
The neurobiological basis of spontaneous alternation
Lalonde, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00041-0 · Cited by 838 · cited 1×
“We note that the performance of wild-type mice declined with age in this task, as has been previously reported (Lalonde, 2002).”
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
BackgroundLemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 5×
“By the age of 40, people who have Down syndrome will also have universally developed neuro- fibrillary tangles in a pattern broadly similar to that of Alzheimer’s disease in the general population (Mann, 1988; Lemere et al., 1996; Leverenz and Raskind, 1998).”
BackgroundResultInfluentialA genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · cited 2×
“Down syndrome is the biggest single genetic risk factor for Alzheimer’s disease (Wiseman et al. , 2015).”
Self-citationSalehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · cited 1×
“…does not alter intrinsic -secretase carboxypeptidase activity Impairment of -secretase carboxypeptidase activity, such as is caused by some familial Alzheimer’s disease mutations in APP or PSEN1 or PSEN2, can result in similar changes to the amyloid-b isoform ratios (Chavez-Gutierrez et al., 2012).”
BackgroundSelf-citationAntiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.027 · Cited by 465 · cited 1×
“Reduced activity of the enzymes inhibited by CSTB have been linked to altered clearance of amyloid-b and processing of APP; including a shift in the amyloid-b40/42 ratio (Mueller-Steiner et al., 2006; Hook et al., 2009; Wang et al., 2015).”
An Aneuploid Mouse Strain Carrying Human Chromosome 21 with down Syndrome Phenotypes.
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M. L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., et al. (2005) · Science · doi:10.1126/science.1114535 · Cited by 434 · cited 9×
“some cells; we previously determined that 66% of brain nuclei retain the chromosome (O’Doherty et al., 2005).”
BackgroundMethodInfluentialSelf-citationYang, D.-S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., et al. (2011) · Brain · doi:10.1093/brain/awq341 · Cited by 429 · cited 1×
“An endogenous inhibitor of lysosomal cathepsins, CSTB, which reduces amyloid-b accumulation when knocked-out, is also found on chromosome 21 (Yang et al., 2011).”
Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del-Favero, J., Cruts, M., Duijn, C. M. V., & Broeckhoven, C. V. (2006) · Brain · doi:10.1093/brain/awl203 · Cited by 407 · cited 1×
“(Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) making it likely that three copies of APP are important in the development of Down syndrome–Alzheimer’s disease.”
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363 · cited 2×
“This is consistent with the site of earliest deposition of amyloid-b occurring intracellularly in the brains of people who have Down syn- drome (Lemere et al., 1996; Mori et al., 2002; Cataldo et al., 2004).”
BackgroundSannerud, R., Esselens, C., Ejsmont, P., Mattera, R., Rochin, L., Tharkeshwar, A. K., De Baets, G., De Wever, V., Habets, R., Baert, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.020 · Cited by 299
Jiang, Y., Mullaney, K. A., Peterhoff, C. M., Che, S., Schmidt, S. D., Boyer-Boiteau, A., Ginsberg, S. D., Cataldo, A. M., Mathews, P. M., & Nixon, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908953107 · Cited by 292
Das, U., Scott, D. A., Ganguly, A., Koo, E. H., Tang, Y., & Roy, S. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.035 · Cited by 282 · cited 1×
“The specific effect of trisomy of chromosome 21 on the synapses of CA3 cells may contribute to their vulnerability to intracellular amyloid-b accumulation, as the synapse is proposed to be a key site of amyloid-b formation (Das et al. , 2013).”
Intraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles
Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255 · cited 2×
“This is consistent with the site of earliest deposition of amyloid-b occurring intracellularly in the brains of people who have Down syn- drome (Lemere et al., 1996; Mori et al., 2002; Cataldo et al., 2004).”
BackgroundIntraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
Alzheimer's disease and Down's syndrome
MANN, D. M. A. (1988) · Histopathology · doi:10.1111/j.1365-2559.1988.tb02018.x · Cited by 245 · cited 2×
“A proportion of people with Down syndrome start to accumulate amyloid-b within their brain in childhood (Lemere et al. , 1996; Leverenz and Raskind, 1998), and the vast majority of individuals will have accumulated substantial amounts of amyloid-b by their mid-20s (Mann, 1988).”
Xiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Tripoli, D. L., Czerniewski, L., Ballabio, A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0705-15.2015 · Cited by 238
A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions
Yu, T., Li, Z., Jia, Z., Clapcote, S. J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq179 · Cited by 237 · cited 3×
“However, we note that as with all models of Down syndrome (including the triple trisomics) (Yu et al. , 2010), the Tc1 mouse does not have the full complement of chromosome 21 sequences (Gribble et al. , 2013).”
Ryoo, S., Cho, H., Lee, H., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227 · cited 1×
“The kinase DYRK1A can phosphorylate APP and alter the protein’s stability and the formation of amyloid-b (Ryoo et al., 2008; Garcia-Cerro et al., 2017).”
Kang, J.-E., Cirrito, J. R., Dong, H., Csernansky, J. G., & Holtzman, D. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700148104 · Cited by 219 · cited 1×
“All mice were co-housed throughout the study as lone-housing is known to modify APP-related phenotypes (Kang et al., 2007); mice were housed with littermates and/or animals of the same sex weaned at the same time, thus mice of differing genotypes were co-housed pseudo-randomly.”
BackgroundLeverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214 · cited 2×
“A proportion of people with Down syndrome start to accumulate amyloid-b within their brain in childhood (Lemere et al. , 1996; Leverenz and Raskind, 1998), and the vast majority of individuals will have accumulated substantial amounts of amyloid-b by their mid-20s (Mann, 1988).”
A prospective 14‐year longitudinal follow‐up of dementia in persons with Down syndrome
McCarron, M., McCallion, P., Reilly, E., & Mulryan, N. (2014) · Journal of Intellectual Disability Research · doi:10.1111/jir.12074 · Cited by 194 · cited 1×
“The vast majority of people who have Down syndrome will develop early-onset Alzheimer’s disease dementia, for example, it is estimated that by their 60s, approximately two-thirds of individuals will have clinical dementia (McCarron et al. , 2014).”
Positive and negative regulation of APP amyloidogenesis by sumoylation
Li, Y., Wang, H., Wang, S., Quon, D., Liu, Y.-W., & Cordell, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0235361100 · Cited by 165 · cited 1×
“These include SUMO3 , which is conjugated to proteins to regulate their function and may influence APP processing (Li et al. , 2003; Dorval et al. , 2007).”
Sun, X., He, G., & Song, W. (2006) · The FASEB Journal · doi:10.1096/fj.05-5632com · Cited by 158
Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
Szaruga, M., Veugelen, S., Benurwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., Ryan, N. S., Lashley, T., Fox, N. C., Murayama, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150892 · Cited by 155 · cited 3×
“…by ELISA Amyloid-b38, amyloid-b40 and amyloid-b42 product levels were quantified on Multi-Spot 96 well plates pre-coated with antiamyloid-b38, amyloid-b40, and amyloid-b42 antibodies obtained from Janssen Pharmaceutica using multiplex MSD technology, as described before (Szaruga et al., 2015).”
MethodInfluentialSelf-citationHyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 149 · cited 1×
“…who have Down syndrome and sporadic Alzheimer’s disease have suggested that higher levels of aggregated amyloid-b accumulate in people who have Down syndrome (Hyman et al. , 1995; Egensperger et al. , 1999; Wilcock et al. , 2015), consistent with the finding in our mouse model system presented here.”
Down syndrome: searching for the genetic culprits
Lana-Elola, E., Watson-Scales, S. D., Fisher, E. M. C., & Tybulewicz, V. L. J. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.008078 · Cited by 146
Self-citationEvaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
Hölttä, M., Hansson, O., Andreasson, U., Hertze, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066381 · Cited by 143 · cited 2×
“Multimeric amyloid-b ELISA Multimeric amyloid-b was measured as described before in detail (Holtta et al., 2013).”
MethodSelf-citationShankar, G. M., Leissring, M. A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D. J., Lemere, C. A., & Walsh, D. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.021 · Cited by 141 · cited 2×
“Total cortical proteins were fractionated based on the method in Shankar et al. (2009).”
MethodDyrk1 inhibition improves Alzheimer's disease‐like pathology
Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V., Shaw, A. Y., Foley, C., Smith, B., Hulme, C., Dunckley, T., Meechoovet, B., et al. (2017) · Aging Cell · doi:10.1111/acel.12648 · Cited by 129 · cited 1×
“Recently, a novel inhibitor of DYRK1A has been shown to reduce amyloid-b plaque load in an Alzheimer’s disease mouse model (Branca et al. , 2017).”
BACE1 and BACE2 enzymatic activities in Alzheimer’s disease
Ahmed, R. R., Holler, C. J., Webb, R. L., Li, F., Beckett, T. L., & Murphy, M. P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06528.x · Cited by 127 · cited 1×
“BACE1 b -secretase activity assay BACE1 b -secretase activity was measured as described previously (Ahmed et al. , 2010).”
Self-citationHOOK, V. Y. H., Kindy, M. S., Reinheckel, T., Peters, C., & Hook, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.131 · Cited by 122
Papavassiliou, P., York, T. P., Gursoy, N., Hill, G., Nicely, L. V., Sundaram, U., McClain, A., Aggen, S. H., Eaves, L., Riley, B., et al. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32729 · Cited by 120
The population prevalence of Down’s syndrome in England and Wales in 2011
Wu, J., & Morris, J. K. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.294 · Cited by 114
Wilcock, D. M., Hurban, J., Helman, A. M., Sudduth, T. L., McCarty, K. L., Beckett, T. L., Ferrell, J. C., Murphy, M. P., Abner, E. L., Schmitt, F. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.016 · Cited by 110 · cited 1×
“Alzheimer’s disease have suggested that higher levels of aggregated amyloid-b accumulate in people who have Down syndrome (Hyman et al., 1995; Egensperger et al., 1999; Wilcock et al., 2015), consistent with the finding in our mouse model system presented here.”
Self-citationLana-Elola, E., Watson-Scales, S., Slender, A., Gibbins, D., Martineau, A., Douglas, C., Mohun, T., Fisher, E. M., & Tybulewicz, V. L. (2016) · eLife · doi:10.7554/elife.11614 · Cited by 110
Self-citationDeletion of glutamate receptor-A (GluR-A) AMPA receptor subunits impairs one-trial spatial memory.
Sanderson, D. J., Gray, A., Simon, A., Taylor, A. M., Deacon, R. M. J., Seeburg, P. H., Sprengel, R., Good, M. A., Rawlins, J. N. P., & Bannerman, D. M. (2007) · Behavioral Neuroscience · doi:10.1037/0735-7044.121.3.559 · Cited by 107 · cited 1×
“Spatial novelty preference was assessed in an enclosed Perspex (cid:2) Y-maze as described previously (Sanderson et al. , 2007).”
Self-citationProtein expression of BACE1, BACE2 and APP in Down syndrome brains
Cheon, M. S., Dierssen, M., Kim, S. H., & Lübec, G. (2007) · Amino Acids · doi:10.1007/s00726-007-0618-9 · Cited by 106
Survival among people with Down syndrome: a nationwide population-based study in Denmark
Zhu, J. L., Hasle, H., Correa, A., Schendel, D., Friedman, J. M., Olsen, J., & Rasmussen, S. A. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.93 · Cited by 106 · cited 1×
“…21 mosaicism, in individuals who have Down syndrome, is associated with higher IQ, earlier acquisition of developmental milestones, less severe cardiac defects and reduced mortality compared to matched cases of non-mosaic chromosome 21 trisomy (Papavassiliou et al. , 2009; Zhu et al. , 2013).”
Chávez-Gutiérrez, L., Tolia, A., Maes, E., Li, T., Wong, P. C., & de Strooper, B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803040200 · Cited by 105 · cited 1×
“Expression and purification of wild-type C99-3xFLAG substrate Human wild-type APPC99-3xFLAG substrate was expressed in COS1 or HEK cells and purified as previously described (Chavez-Gutierrez et al., 2008).”
MethodSelf-citationGlasson, E. J., Jacques, A., Wong, K., Bourke, J., & Leonard, H. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.10.083 · Cited by 105 · cited 1×
“Changes in social attitudes and improvements in medical care have led to a significant rise in life expectancy for people who have Down syndrome (Glasson et al. , 2016).”
Gribble, S. M., Wiseman, F. K., Clayton, S., Prigmore, E., Langley, E., Yang, F., Maguire, S., Fu, B., Rajan, D., Sheppard, O., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060482 · Cited by 102 · cited 3×
“However, we note that as with all models of Down syndrome (including the triple trisomics) (Yu et al. , 2010), the Tc1 mouse does not have the full complement of chromosome 21 sequences (Gribble et al. , 2013).”
Self-citationGarcía-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100
Morice, E., Andreae, L. C., Cooke, S. F., Vanes, L., Fisher, E. M. C., Tybulewicz, V. L. J., & Bliss, T. V. P. (2008) · Learning & Memory · doi:10.1101/lm.969608 · Cited by 98 · cited 1×
“…well-defined Down syndrome-associated deficits, including defects in nervous system function such as in long-term potentiation, short-term memory, dendritic spine morphology and connectivity in the hippocampus (O’Doherty et al. , 2005; Morice et al. , 2008; Witton et al. , 2015; Hall et al. , 2016).”
Self-citationClinical aspects and biomarkers of Alzheimer's disease in Down syndrome
Zis, P., & Strydom, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.024 · Cited by 95 · cited 1×
“A recent review has noted that this pattern of clinical presentation is more similar to that seen in familial cases of Alzheimer’s disease caused by mutations in APP that decrease amyloid-b 40/42 ratio, than to cases of diseases caused by duplication of APP (Zis and Strydom, 2018).”
Self-citationDorval, V., Mazzella, M. J., Mathews, P. M., Hay, R. T., & Fraser, P. E. (2007) · Biochemical Journal · doi:10.1042/bj20061451 · Cited by 70
The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome
Startin, C. M., Hamburg, S., Hithersay, R., Davies, A., Rodger, E., Aggarwal, N., Al-Janabi, T., & Strydom, A. (2016) · Wellcome Open Research · doi:10.12688/wellcomeopenres.9961.1 · Cited by 66 · cited 1×
“This approach is also being developed to improve the assessment of cognitive decline in adults who have Down syndrome (Startin et al. , 2016).”
Self-citationVandersteen, A., Masman, M. F., Baets, G. D., Jonckheere, W., van der Werf, K., Marrink, . J., Rozenski, J., Benilova, I., Strooper, B. D., Subramaniam, V., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394635 · Cited by 58 · cited 1×
“…soluble amyloid-b40/42 ratio The aggregation rate of amyloid-b in vitro is influenced by the relative abundance of more aggregate prone amyloid-b species, such as amyloid-b42, compared with forms of the peptide, which are less able to seed aggregation such as amyloid-b40 (Vandersteen et al., 2012).”
BackgroundAltered regulation of tau phosphorylation in a mouse model of down syndrome aging
Sheppard, O., Plattner, F., Rubin, A., Slender, A., Linehan, J. M., Brandner, S., Tybulewicz, V. L. J., Fisher, E. M. C., & Wiseman, F. K. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.025 · Cited by 57 · cited 3×
“, 2005), which carries a freely segregating chromosome 21 and is trisomic for 75% of the genes on this chromosome but, importantly, is not functionally triplicated for APP (Sheppard et al., 2012; Gribble et al., 2013).”
BackgroundSelf-citationCathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments
Wang, H., Sang, N., Zhang, C., Raghupathi, R., Tanzi, R. E., & Saunders, A. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00329 · Cited by 49 · cited 1×
“Reduced activity of the enzymes inhibited by CSTB have been linked to altered clearance of amyloid-b and processing of APP; including a shift in the amyloid-b 40/42 ratio (Mueller-Steiner et al. , 2006; Hook et al. , 2009; Wang et al. , 2015).”
Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome
Mok, K. Y., Jones, E. L., Hanney, M., Harold, D., Sims, R., Williams, J., Ballard, C., & Hardy, J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.022 · Cited by 48 · cited 1×
“BACE2 , a homologue of BACE1 located on chromosome 21 may impair the formation of amyloid-b by cleaving APP within the amyloid-b region (Sun et al. , 2006; Mok et al. , 2014).”
Self-citationPopov, V. I., Kleschevnikov, A. M., Klimenko, O. A., Stewart, M. G., & Belichenko, P. V. (2011) · Journal of Comparative Neurology · doi:10.1002/cne.22573 · Cited by 48 · cited 1×
“The sensitivity of the CA3 to trisomy of chromosome 21 is also observed in an alternative Down syndrome mouse model (Popov et al. , 2011).”
Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome
Hirayama, A., Horikoshi, Y., Maeda, M., Ito, M., & Takashima, S. (2003) · Brain and Development · doi:10.1016/s0387-7604(02)00209-7 · Cited by 47 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
BackgroundHippocampal circuit dysfunction in the Tc1 mouse model of Down syndrome
Witton, J., Padmashri, R., Zinyuk, L. E., Popov, V. I., Kraev, I., Line, S. J., Jensen, T. P., Tedoldi, A., Cummings, D. M., Tybulewicz, V. L. J., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4072 · Cited by 46 · cited 2×
“A previous study using the Tc1 mouse showed that the CA3 has a particular vulnerability to trisomy of chromosome 21, which includes a specific reduction in synapse number, alterations to synapse architecture and related electrophysiological and behavioural deficits (Witton et al. , 2015).”
Self-citationBrault, V., Pereira, P., Duchon, A., & Hérault, Y. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020086 · Cited by 42 · cited 1×
“Further studies in alternative mouse models of Down syndrome that are not mosaic, in particular mice with segmental duplications of the mouse genome orthologous to regions of human chromosome 21, may help investigate this (Brault et al. , 2006; Yu et al. , 2010; Lana-Elola et al. , 2011, 2016).”
Tc1 mouse model of trisomy-21 dissociates properties of short- and long-term recognition memory
Hall, J. H., Wiseman, F. K., Fisher, E., Tybulewicz, V. L. J., Harwood, J. L., & Good, M. A. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.02.002 · Cited by 27 · cited 1×
“…Down syndrome- associated deficits, including defects in nervous system func- tion such as in long-term potentiation, short-term memory, dendritic spine morphology and connectivity in the hippo- campus (O’Doherty et al., 2005; Morice et al., 2008; Witton et al., 2015; Hall et al., 2016).”
BackgroundSelf-citationCharacterization of the Brain β-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice
Mustafiz, T., Portelius, E., Gustavsson, M. K., Hölttä, M., Zetterberg, H., Blennow, K., Nordberg, A. K., & Lithner, C. U. (2011) · Neurodegenerative Diseases · doi:10.1159/000323871 · Cited by 24 · cited 1×
“Mass-spectrometry analysis of amyloid-b in fractionated cortical proteins Amyloid-b was immunoprecipitated using the KingFisher magnetic particle processor (Thermo Fisher Scientific) and mass spectrometric analysis using MALDI-TOF MS were performed as described previously (Mustafiz et al., 2011).”
MethodSelf-citationEgensperger, R., Weggen, S., Ida, N., Multhaup, G., Schnabel, R., Beyreuther, K. T., & Bayer, T. A. (1999) · Acta Neuropathologica · doi:10.1007/s004010050963 · Cited by 21 · cited 1×
“…who have Down syndrome and sporadic Alzheimer’s disease have suggested that higher levels of aggregated amyloid-b accumulate in people who have Down syndrome (Hyman et al. , 1995; Egensperger et al. , 1999; Wilcock et al. , 2015), consistent with the finding in our mouse model system presented here.”
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., Roqué Figuls, M., Alcolea, D., Videla, L., Barroeta, I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12910 · Cited by 195
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176
Self-citation
Metadata
- Authors
- Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., Collins, T., Powell, C., Sarell, C. J., Rickman, M., Choong, X., Tosh, J. L., Siganporia, C., Whittaker, H. T., Stewart, F., Szaruga, M., London Down syndrome consortium, Murphy, M. P., Blennow, K., de Strooper, B., Zetterberg, H., Bannerman, D., Holtzman, D. M., Tybulewicz, V. L. J., Fisher, E. M. C., The LonDownS Consortium, Strydom, A., Fisher, E., Nizetic, D., Hardy, J., Tybulewicz, V., & Karmiloff-Smith, A.
- Affiliations
- King's College London (GB)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- Washington University in St. Louis (US)
- University of Gothenburg (SE)
- University of Kentucky (US)
- VIB-KU Leuven Center for Brain and Disease Research, VIB-Leuven 3000, Center for Human Genetics, Universitaire Ziekenhuizen and LIND, KU Leuven, Leuven, Belgium
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG UK
- MRC Prion Unit (GB)
- UK Dementia Research Institute (GB)
- The LonDownS Consortium, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London, SE5 8AF, UK
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-26
- Volume
- 141
- Issue
- 8
- Pages
- 2457-2474
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6061702
- OpenAlex
- W2810011474
- Cited by
- 133
- References
- 68
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 4
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Wellcome Trust Strategic Award (098330/Z/12/Z)
- London Down Syndrome (LonDownS) Consortium
- Wellcome Trust Joint Senior Investigators Award
- Medical Research Council (U117527252, G0601056, FC001194)
- Alzheimer’s Research UK
- Alzheimer’s Society
- Epilepsy Research UK
- Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences
- Francis Crick Institute
- Cancer Research UK (FC001194)
- Wellcome Trust (FC001194)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, amyloid-beta deposition, amyloid plaques, Alzheimer's disease, amyloid-beta aggregation, cognitive impairment, gamma-secretase, APP, mouse model
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Down Syndrome, Female, Humans, Male, Mice, Inbred C57BL, Trisomy, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.